Brief: Terns Pharmaceuticals Announces Data From Ongoing Phase 1 Pharmacokinetic Study Of Allosteric Bcr-Abl Inhibitor Tern-701
29/04/2024 21:22
April 29 (Reuters) - Terns Pharmaceuticals Inc TERN.O :
* TERNS PHARMACEUTICALS ANNOUNCES DATA FROM ONGOING PHASE 1
PHARMACOKINETIC STUDY OF ALLOSTERIC BCR-ABL INHIBITOR TERN-701
IN ADULT HEALTHY VOLUNTEERS AND HIGHLIGHTS POTENTIAL FOR
COMPETITIVE DIFFERENTIATION
* TERNS PHARMACEUTICALS INC - INTERIM DATA FROM PHASE 1
CARDINAL
TRIAL INITIAL COHORTS ANTICIPATED IN SECOND HALF OF 2024
* TERNS PHARMACEUTICALS INC - PHARMACOKINETIC DATA SHOW NO
CLINICALLY SIGNIFICANT DIFFERENCE IN EXPOSURE BETWEEN FED AND
FASTED DOSING
Source text for Eikon: ID:nGNX3llx2C
Further company coverage: TERN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Terns Pharmaceuticals
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
Brief: Merck Announces Expiration Of Hart-Scott-Rodino Act Waiting Period To Acquire Terns Pharmaceuticals
Brief: Merck Begins Tender Offer To Acquire Terns Pharmaceuticals, Inc.